Literature review of outcomes of treatment of CMV anterior uveitis in non–HIV-positive patients
| Authors | No. eyes treated | Treatment modality and duration in months | Outcome | Duration of follow-up (months) |
| Chee et al2 | 12 | Intravenous ganciclovir at 5 mg/kg of body weight twice a day for 6 weeks, followed by oral ganciclovir at 1 g three times a day for another 6 weeks or oral valganciclovir at 900 mg twice a day for 6 weeks, followed by 450 mg twice a day for another 6 weeks, 9 cases; 12 weeks of intravitreal ganciclovir at 2 mg/week, 3 cases | 1 responded with no recurrence, 6 responded but had recurrences, 2 had no response, 2 responded with no recurrence and 1 had recurrences | 14–43 |
| Mietz et al5 | 1 | Intravenous ganciclovir at 450 mg twice daily×4 weeks and oral 3 g/day×19 weeks | Responded but recurred | Unknown |
| Markomichelakis et al6 | 2 | Oral ganciclovir at 3 g/day×52 weeks, 1 case; oral ganciclovir at 3 g/day×104 weeks, 1 case | Both responded with no recurrences | Unknown |
| De Schryver et al7 | 5 | Intravenous ganciclovir or foscarnet×2 weeks followed by oral valganciclovir 450 mg twice daily×8 weeks, 4 cases; 12 weeks oral valganciclovir, 1 case | 3 responded but recurred; retreated with oral valganciclovir for 6 months, responded with no recurrence | 9–24 |
| Van Boxtel et al8 | 5 | Oral valganciclovir at 900 mg twice daily×3 weeks followed by 900 mg/day for 3–12 months | All responded; two had recurrences | 18–249 |
| Chung and Chua10 | 1 | 1 dose intravitreal ganciclovir | Responded with no recurrence | Unknown |
| Sira and Murray12 | 1 | 11 months oral valaciclovir at 1 g twice a day | Responded with no recurrence | 11 |
| Hwang et al18 | 6 | 1 dose of intravitreal 2 mg ganciclovir followed by oral valganciclovir at 900 mg twice a day×1–4 months, 4 cases; 1 dose of intravitreal ganciclovir at 2 mg, 2 cases | Responded with no recurrence | 12–22 |